Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Share-based Compensation: 2015-2024

Historic Share-based Compensation for Kura Oncology (KURA) over the last 10 years, with Dec 2024 value amounting to $33.9 million.

  • Kura Oncology's Share-based Compensation rose 31.73% to $11.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $34.4 million, marking a year-over-year change of. This contributed to the annual value of $33.9 million for FY2024, which is 20.71% up from last year.
  • Per Kura Oncology's latest filing, its Share-based Compensation stood at $33.9 million for FY2024, which was up 20.71% from $28.1 million recorded in FY2023.
  • In the past 5 years, Kura Oncology's Share-based Compensation registered a high of $33.9 million during FY2024, and its lowest value of $12.8 million during FY2020.
  • Over the past 3 years, Kura Oncology's median Share-based Compensation value was $28.1 million (recorded in 2023), while the average stood at $29.4 million.
  • Data for Kura Oncology's Share-based Compensation shows a peak YoY surged of 84.11% (in 2021) over the last 5 years.
  • Over the past 5 years, Kura Oncology's Share-based Compensation (Yearly) stood at $12.8 million in 2020, then skyrocketed by 84.11% to $23.6 million in 2021, then increased by 11.62% to $26.3 million in 2022, then increased by 6.70% to $28.1 million in 2023, then climbed by 20.71% to $33.9 million in 2024.